Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

34.0%

32 terminated/withdrawn out of 94 trials

Success Rate

51.5%

-35.0% vs industry average

Late-Stage Pipeline

5%

5 trials in Phase 3/4

Results Transparency

109%

37 of 34 completed trials have results

Key Signals

9 recruiting37 with results19 terminated13 withdrawn

Enrollment Performance

Analytics

Phase 1
45(48.9%)
Phase 2
41(44.6%)
Phase 3
5(5.4%)
Early Phase 1
1(1.1%)
92Total
Phase 1(45)
Phase 2(41)
Phase 3(5)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (94)

Showing 20 of 94 trials
NCT02227251Phase 2Active Not Recruiting

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Role: lead

NCT04442022Phase 2Active Not Recruiting

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Role: lead

NCT02343042Phase 1Active Not Recruiting

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Role: lead

NCT04898894Phase 1Active Not Recruiting

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Role: collaborator

NCT05611931Phase 3Recruiting

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Role: lead

NCT02436707Phase 2Active Not Recruiting

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Role: collaborator

NCT03555422Phase 3Completed

Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

Role: lead

NCT04562389Phase 3Active Not Recruiting

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

Role: lead

NCT07479979Phase 1Not Yet Recruiting

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

Role: collaborator

NCT07200102Phase 1Recruiting

Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma

Role: collaborator

NCT07447817Phase 2Not Yet Recruiting

Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

Role: collaborator

NCT04925193Phase 2Active Not Recruiting

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Role: collaborator

NCT07215832Unknown

Karyopharm Expanded Access Program for Selinexor

Role: lead

NCT05530421Phase 2Recruiting

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

Role: collaborator

NCT05980806Phase 2Recruiting

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Role: lead

NCT04661137Phase 2Suspended

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

Role: collaborator

NCT04414475Phase 2Recruiting

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Role: lead

NCT04856189Phase 1Terminated

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Role: collaborator

NCT04914845Phase 1Completed

KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia

Role: collaborator

NCT07362225Recruiting

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

Role: collaborator